AVITA Medical Files 8-K on Financials
Ticker: AVHHL · Form: 8-K · Filed: Jan 7, 2025 · CIK: 1762303
| Field | Detail |
|---|---|
| Company | Avita Medical, Inc. (AVHHL) |
| Form Type | 8-K |
| Filed Date | Jan 7, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
AVITA Medical dropped an 8-K on Jan 7th detailing their financial results. Check it out.
AI Summary
AVITA Medical, Inc. filed an 8-K on January 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Valencia, California.
Why It Matters
This filing provides crucial updates on AVITA Medical's financial performance and condition, which is essential for investors to assess the company's health and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial reporting filing and does not contain information that inherently increases risk.
Key Players & Entities
- AVITA Medical, Inc. (company) — Registrant
- January 07, 2025 (date) — Date of earliest event reported
- Valencia, California (location) — Address of Principal Executive Offices
FAQ
What specific financial information is detailed in this 8-K filing?
The filing is categorized under 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.
When was this 8-K report filed?
The report was filed on January 7, 2025.
What is the principal business address of AVITA Medical, Inc.?
The principal executive offices are located at 28159 Avenue Stanford, Suite 220, Valencia, California, 91355.
What is AVITA Medical, Inc.'s state of incorporation?
AVITA Medical, Inc. is incorporated in Delaware.
What is the Commission File Number for AVITA Medical, Inc.?
The Commission File Number is 001-39059.
Filing Stats: 491 words · 2 min read · ~2 pages · Grade level 11.6 · Accepted 2025-01-07 16:43:08
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share RCEL The Nasdaq Stock Mar
Filing Documents
- rcel-20250107.htm (8-K) — 39KB
- rcel-ex99_1.htm (EX-99.1) — 24KB
- img262816717_0.jpg (GRAPHIC) — 20KB
- img262816717_1.jpg (GRAPHIC) — 20KB
- 0000950170-25-002907.txt ( ) — 241KB
- rcel-20250107.xsd (EX-101.SCH) — 26KB
- rcel-20250107_htm.xml (XML) — 5KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On January 7, 2025, AVITA Medical, Inc. issued a press release announcing an update to its expected fourth quarter and full year 2024 revenue and provided its 2025 financial guidance. A copy of the press release is attached hereto as Exhibit 99.1. The information under this Item 2.02 and Exhibit 99.1 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be deemed incorporated by reference into any filing made under the Securities Act of 1933 except as expressly set forth by specific reference in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. 99.1 AVITA Medical Updates Expected Fourth Quarter and Full Year 2024 Revenue, Provides 2025 Financial Guidance 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AVITA Medical, Inc. Date: January 7, 2025 By: /s/ David O'Toole David O'Toole Chief Financial Officer